Yersal Özlem, Odabaşi Eylem, Özdemir Özge, Kemal Yasemin
Department of Medical Oncology, Adnan Menderes University, Aydın 09010, Turkey.
Department of Radiation Oncology, Samsun Research and Training Hospital, Samsun 05000, Turkey.
Mol Clin Oncol. 2018 Oct;9(4):453-458. doi: 10.3892/mco.2018.1695. Epub 2018 Aug 9.
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. Identification of accessible and cost-effective prognostic factors may better guide adjuvant treatment-related decisions. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are markers of host inflammatory response, and their increase has recently been shown to be a poor prognostic factor in several malignancies. The aim of the present study was to investigate the prognostic value of preoperative NLR and PLR in GBM patients. Between 2012 and 2017, 104 patients who had undergone surgery for GBM were considered for adjuvant therapy in our institution. Of those, 80 patients with evaluable pre-corticosteroid full blood count results were identified and included in the final analysis. The Eastern Cooperative Oncology Group performance status, localization, radiochemotherapy and second-line systemic therapy were found to be independent prognostic indicators for progression-free and overall survival. The median overall survival was 13.2 months. Patients with NLR <4 had a better median overall survival of 10.7 vs. 7.8 months in patients with NLR >4; however, this difference was not statistically significant (P>0.05). Overall survival also did not differ significantly between patients with low and those with high PLR values (10.2 vs. 15.2 months, respectively; P=0.105). In conclusion, the results of the present study suggest that pre-treatment NLR and PLR do not have prognostic value in GBM patients; however, large-scale trials are required to confirm these findings.
多形性胶质母细胞瘤（GBM）是成人中最常见且侵袭性最强的原发性脑肿瘤。识别可及且具成本效益的预后因素可能会更好地指导辅助治疗相关决策。中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）是宿主炎症反应的标志物，最近研究表明它们的升高在多种恶性肿瘤中是不良预后因素。本研究的目的是探讨术前NLR和PLR在GBM患者中的预后价值。2012年至2017年间，在我们机构有104例接受过GBM手术的患者被考虑进行辅助治疗。其中，80例具有可评估的皮质类固醇治疗前全血细胞计数结果的患者被识别并纳入最终分析。东部肿瘤协作组体能状态、肿瘤位置、放化疗及二线全身治疗被发现是无进展生存期和总生存期的独立预后指标。中位总生存期为13.2个月。NLR<4的患者中位总生存期较好，为10.7个月，而NLR>4的患者为7.8个月；然而，这种差异无统计学意义（P>0.05）。低PLR值患者和高PLR值患者的总生存期也无显著差异（分别为10.2个月和15.2个月；P=0.105）。总之，本研究结果表明，治疗前NLR和PLR在GBM患者中不具有预后价值；然而，需要大规模试验来证实这些发现。
